<?xml version="1.0" encoding="UTF-8"?>
<ref id="B43">
 <label>43.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Green</surname>
    <given-names>CA</given-names>
   </name>
   <name>
    <surname>Scarselli</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Voysey</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Capone</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Vitelli</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Nicosia</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults</article-title>. 
  <source>BMJ Open</source> (
  <year>2015</year>) 
  <volume>5</volume>:
  <fpage>e008748</fpage>. 
  <pub-id pub-id-type="doi">10.1136/bmjopen-2015-008748</pub-id>
  <?supplied-pmid 26510727?>
  <pub-id pub-id-type="pmid">26510727</pub-id>
 </mixed-citation>
</ref>
